Ausgewählte Studien

J Dtsch Dermatol Ges. 2021 Aug;19(8):1170-1177. doi: 10.1111/ddg.14451_g. NO ABSTRACT PMID:34390146 | DOI:10.1111/ddg.14451_g Den ganzen Artikel lesen

Shivkar Amara, Corresponding Author Shivkar Amara [email protected] The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine …Den ganzen Artikel lesen

Cristina Galache, Cristina Galache Department of Dermatology, Hospital Universitario Central de Asturias, Oviedo, Spain Group of Investigation on …Den ganzen Artikel lesen

Journal of the European Academy of Dermatology and Venereology Volume 38, Issue 3 p. 460-461 Free Access Jacek C. Szepietowski, Corresponding Author Jacek …Den ganzen Artikel lesen

MMW Fortschr Med. 2022 Jan;164(1):27. doi: 10.1007/s15006-022-0698-1. NO ABSTRACT PMID:35043321 | DOI:10.1007/s15006-022-0698-1 Den ganzen Artikel lesen

Z Rheumatol. 2023 Mar 1. doi: 10.1007/s00393-023-01326-5. Online ahead of print. ABSTRACT Psoriatic arthritis (PsA) is a systemic immune-mediated inflammatory disease of the musculoskeletal system, which is accompanied by a chronic and progressive course. It is characterized by different clinical manifestations and can severely impair the quality of life and function of patients due to the existing heterogeneity of the manifestations. The (early) diagnosis of PsA and individualized therapeutic m

Wang Y, Song ZB, Deng XR, Zhang XH, Zhang ZL. Wang Y, et al. Chin Med J (Engl). 2021 Oct 20;134(21):2564-2572. doi: 10.1097/CM9.0000000000001810. …Den ganzen Artikel lesen

Hautarzt. 2021 Nov;72(11):946-952. doi: 10.1007/s00105-021-04892-4. Epub 2021 Sep 30. ABSTRACT BACKGROUND: Psoriatic arthritis is the most important "comorbidity" of psoriasis, which impacts the work of dermatologists in many ways. OBJECTIVE: The relevance of joint involvement in psoriasis patients for the practicing dermatologist is considered. METHODS: An analysis of publications listed in PubMed® (Bethesda, MD, USA) on the topic of psoriatic arthritis in English, German, or French was carried

Kaaz K, Szepietowski JC, Matusiak Ł. Kaaz K, et al. Acta Derm Venereol. 2019 Feb 1;99(2):175-180. doi: 10.2340/00015555-3065. Acta Derm Venereol. …Den ganzen Artikel lesen

1. Introduction Pain is defined as “an unpleasant sensory or emotional experience associated with or resembling that associated with actual or …Den ganzen Artikel lesen

• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE …Den ganzen Artikel lesen

Front Med (Lausanne) . 2024 Oct 29;11:1458394. doi: 10.3389/fmed.2024.1458394 Max Nordgren 1Diagnostic Center Dermatology, Malmö, Sweden 2Deparment of …Den ganzen Artikel lesen

Full text linksCite Display options Display options The aim of this review is to provide a summary of the botany, phytochemistry and dermatological …Den ganzen Artikel lesen

Hautarzt. 2021 Sep 20. doi: 10.1007/s00105-021-04885-3. Online ahead of print. ABSTRACT BACKGROUND: With AtopicHealth1, the first national care study on atopic dermatitis (AD) was conducted in 2010. At that time, about one third of the patients undergoing treatment by dermatologists showed severe limitations in quality of life, which indicated an insufficient quality of care. The aim of the present study was to characterise the current care of patients with AD undergoing dermatological treatment

essential oil/fixed oil, biological source, family (plant part) method/type of analysis identified metabolites (major) pharmacological activity essential …Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2021 Dec 15. doi: 10.1007/s13555-021-00658-x. Online ahead of print. ABSTRACT INTRODUCTION: Psoriasis is a systemic inflammatory disease characterised by pruritic skin lesions that impair quality of life (QOL). Long-Term Documentation of the Utilization of Apremilast in Patients with Plaque Psoriasis under Routine Conditions (LAPIS-PSO; ClinicalTrials.gov: NCT02626793) was a 52-week, prospective, multicentre, observational cohort study conducted in real-world dermatology

Xiaoyan Wu, Xiaoyan Wu Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China Search for more …Den ganzen Artikel lesen

Dermatologie (Heidelb). 2023 Jan 31. doi: 10.1007/s00105-023-05107-8. Online ahead of print. ABSTRACT Psoriasis exacerbation may occur in patients with human immunodeficiency virus (HIV). We present the case of a patient with severe psoriasis vulgaris (PASI 34.2) and an initial HIV diagnosis who showed rapid resolution of psoriasis upon initiation of antiretroviral therapy. Antiretroviral therapy is an effective treatment option for HIV-associated psoriasis. Especially in patients with a sudden

There is a lack of evidence investigating the impact of patient-reported outcomes (PROs) monitoring in routine clinical practice, according to a …Den ganzen Artikel lesen

Biofactors. 2023 May 4. doi: 10.1002/biof.1949. Online ahead of print. ABSTRACT Psoriasis is an immune-mediated inflammatory skin disease driven by interleukin-17A (IL-17A) and associated with cardiovascular dysfunction. We used a severe psoriasis mouse model of keratinocyte IL-17A overexpression (K14-IL-17Aind/+ , IL-17Aind/+ control mice) to investigate the activity of neutrophils and a potential cellular interconnection between skin and vasculature. Levels of dermal reactive oxygen species (R

J Dermatol. 2021 Sep 12. doi: 10.1111/1346-8138.16128. Online ahead of print. ABSTRACT Psoriasis is a common, chronic inflammatory skin disorder negatively impacting health-related quality of life (HRQoL). Guselkumab, targeting interleukin-23 (IL-23), is an approved biologic therapy for psoriasis. PERSIST is an ongoing prospective, noninterventional, long-term, German multicenter study evaluating the effect of guselkumab on HRQoL, and its efficacy and safety in patients with moderate-to-severe p

J Eur Acad Dermatol Venereol. 2022 May 15. doi: 10.1111/jdv.18218. Online ahead of print. ABSTRACT BACKGROUND: PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-world setting. OBJECTIVES: Evaluation of the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in p

Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh JA. Mease PJ, et al. Adv Ther. 2024 Dec 2. doi: 10.1007/s12325-024-03042-1. …Den ganzen Artikel lesen

Actas Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00187-X. doi: 10.1016/j.ad.2024.02.030. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: risankizumab-a humanized monoclonal antibody that targets the p19 subunit of IL-23-has been recently approved to treat moderate-to-severe plaque psoriasis. Real-world data based on a representative pool of patients are currently lacking. OBJECTIVE: To assess the mid- and long-term safety and efficacy profile of risankizumab in patients with moderate-to-

J Dtsch Dermatol Ges. 2023 Apr 19. doi: 10.1111/ddg.15030. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVES: Psoriasis is a common skin disorder with a high physical and psychological burden for patients. Up to 30% of the patients are candidates for a systemic treatment. The aim of this study was to describe the characteristics and the real-world systemic treatment of psoriasis patients. PATIENTS AND METHODS: This study was based on German medical claims data. A cross-sectional analysis